European journal of clinical investigation
-
Eur. J. Clin. Invest. · Feb 2023
Randomized Controlled Trial Multicenter StudyEarly administration of tofacitinib in COVID-19 pneumonitis: An open randomised controlled trial.
Controversies on sub-populations most sensitive to therapy and the best timing of starting the treatment still surround the use of immunomodulatory drugs in COVID-19. ⋯ High-dose tofacitinib therapy in patients with COVID pneumonitis is safe and may prevent deterioration to respiratory failure.
-
Eur. J. Clin. Invest. · Feb 2023
Review Meta AnalysisCoronary artery calcium score and its association with stroke: A systematic review and meta-analysis.
The relationship between coronary artery calcium (CAC) score and incident stroke is controversial. ⋯ There is an association between high CAC score and incident stroke, but more studies are needed to determine how patients with incidental CAC should be managed from the perspective of stroke prevention.
-
Eur. J. Clin. Invest. · Feb 2023
Meta AnalysisHelicobacter pylori infection and PD-L1 expression in gastric cancer: a meta-analysis.
High expression of programmed death ligand-1 (PD-L1) has been related to good response to immunotherapy patients with gastric cancer (GC). However, the influence of Helicobacter pylori (HP) infection on PD-L1 expression in GC remains unknown. A meta-analysis was performed to evaluate the association between HP infection and PD-L1 expression in GC. ⋯ Helicobacter pylori infection in GC patients is associated with tumour expression of PD-L1, suggesting HP infection may be a predictor of good response to immunotherapy in GC.
-
Eur. J. Clin. Invest. · Feb 2023
Review Meta AnalysisAn umbrella review and meta-analysis of renin-angiotensin system drugs use and COVID-19 outcomes.
Despite the availability of extensive literature on the effect of angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin-receptor blockers (ARBs) on COVID-19 outcomes, the evidence is still controversial. We aimed to provide a comprehensive assessment of the effect of ACEIs/ARBs on COVID-19-related outcomes by summarising the currently available evidence. ⋯ Collective evidence from observational studies indicate a good quality evidence on the significant association between ACEIs/ARBs use and reduction in death and death/ICU admission, but poor-quality evidence on both reducing severe COVID-19 and increasing hospitalisation. Our findings further support the current recommendations of not discontinuing ACEIs/ARBs therapy in patients with COVID-19.
-
Eur. J. Clin. Invest. · Feb 2023
Meta AnalysisNeutrophil-to-lymphocyte and platelet-to-lymphocyte ratio and disease activity in rheumatoid arthritis: a systematic review and meta-analysis.
Inflammatory indexes derived from routine haematological parameters, particularly the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR), have been shown to discriminate between patients with and without rheumatoid arthritis (RA). However, their capacity to discriminate between RA patients with and without active disease has not been systematically appraised. ⋯ NLR and PLR can significantly discriminate between RA patients with and without active disease. Further studies are required to determine their diagnostic performance, singly or in combination with other parameters, in routine practice.